| 摘要: |
| ［摘要］ 目的 观察尤瑞克林治疗急性大灶脑梗死的临床疗效。方法 选择急性大灶脑梗死患者97例，按随机数字表法分为治疗组（n=50）和对照组（n=47）。两组给予相同的基础治疗，治疗组同时给予尤瑞克林0.15 PNA单位微泵静注，1次/d，疗程14 d。观察两组患者病死率及治疗21 d后梗死灶体积变化，评定两组患者在治疗前后的神经功能缺损程度。结果 （1）治疗组50例患者，退出1例，死亡3例，病死率为6.0%；对照组47例患者，死亡10例，病死率为21.3%，两组病死率差异有统计学意义(P<0.05)。（2）治疗前两组患者CT脑梗死灶体积差异无统计学意义(P>0.05)；治疗21 d两组患者CT低密度灶体积较治疗前均有缩小，治疗组较对照组改善更为明显，组间差异具有统计学意义(P<0.05)；（3）神经功能缺损评定：治疗前及治疗21 d两组患者美国国立卫生研究院卒中量表（NIHSS）评分比较差异无统计学意义(P>0.05)；除l例因合并使用ACEI类降压药而导致血压骤然下降，停用并对症处理后改善。治疗组观察期间未发生明显不良反应。结论 尤瑞克林能够有效降低大灶脑梗死患者的病死率，明显减小脑梗死体积，但患者近期（21 d）神经功能未见明显改善，远期疗效有待进一步观察。 |
| 关键词: 大灶脑梗死 尤瑞克林 疗效 |
| DOI：10.3969/j.issn.1674-3806.2016.11.08 |
| 分类号:R 743 |
| 基金项目:南宁市科学研究与技术开发计划项目（编号：20133138） |
|
| The clinical effect of Urinary Kallidinogenase in treatment of large-scale acute cerebral infarction |
|
MA Li-qin, WEN De-shu, XIE Yao-yi, et al.
|
|
Department of Neurology, the Third People′s Hospital of Nanning City, Guangxi 530003, China
|
| Abstract: |
| ［Abstract］ Objective To observe the clinical effect of Urinary Kallidinogenase in the treatment of large-scale acute cerebral infarction.Methods Ninety-seven patients with large-scale acute cerebral infarction were randomly divided into two groups:the treatment group(n=50) and the control group(n=47). Both of the two groups were treated with a basic therapy, and the treatment group was administrated additional intravenous injection of Urinary Kallidinogenase 0.15 PNAU per day for 21 days. The clinical efficacy, the mortality rate, and the cerebral infarction area and NIHSS(the National Institutes of Health stroke scale, NIHSS) were compared between the two groups.Results （1）In the treatment group,1 case missed, 3 cases died, and the mortality rate was 6.0%. In the control group, 10 cases died, and the mortality rate was 21.3%. There was a significant difference in the mortality rate between the two groups(P<0.05). （2）There was no significant difference in the change of the infarction area between two groups before the treatment(P>0.05). After the treatment, the infarction areas shrank in both of the two groups compared with those before the treatment, and these improved more obviously in the treatment group than those in the control group(P<0.05). （3）There were no significant differences in the scores of NIHSS between the groups before and 21 days after the treatment(P>0.05). One case occurred a sudden drop in blood pressure because of the combining use of ACEI class of antihypertensive drug, whose symptoms were improved by withdrawing the drug and symptomatic treatment. Except for this case, no obvious adverse reactions occurred in the treatment group.Conclusion Urinary Kallidinogenase can effectively reduce the mortality rate and significantly decrease the cerebellar infarction volume in the treatment of large-scale acute cerebral infarction, but it can not obviously improve NIHSS within 21 days after the treatment. The long-term curative effect of Urinary Kallidinogenase remains to be studied. |
| Key words: Large-scale cerebral infarction Urinary Kallidinogenase Clinical effect |
